Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Conditions
- Neovascular Age-Related Macular Degeneration
Interventions
- DRUG: RTH258/Brolucizumab
Sponsor
Novartis Pharmaceuticals